1,166 results on '"Kerr, Keith"'
Search Results
2. Non-small-cell lung cancer
3. Association between pathologic response and survival after neoadjuvant therapy in lung cancer
4. Rediscovering immunohistochemistry in lung cancer
5. ROS1 fusions in resected stage I-III adenocarcinoma: Results from the European Thoracic Oncology Platform Lungscape project
6. Author Correction: The evolution of lung cancer and impact of subclonal selection in TRACERx
7. Differentiating Separate Primary Lung Adenocarcinomas From Intrapulmonary Metastases With Emphasis on Pathological and Molecular Considerations: Recommendations From the International Association for the Study of Lung Cancer Pathology Committee
8. The evolution of non-small cell lung cancer metastases in TRACERx
9. The evolution of lung cancer and impact of subclonal selection in TRACERx
10. International Association for the Study of Lung Cancer Study of Reproducibility in Assessment of Pathologic Response in Resected Lung Cancers After Neoadjuvant Therapy
11. KRAS G12C in advanced NSCLC: Prevalence, co-mutations, and testing
12. IASLC Lung Cancer Staging Project: The New Database to Inform Revisions in the Ninth Edition of the TNM Classification of Lung Cancer
13. An endogenous inhibitor of angiogenesis downregulated by hypoxia in human aortic valve stenosis promotes disease pathogenesis
14. Expert opinion on NSCLC small specimen biomarker testing — Part 2: Analysis, reporting, and quality assessment
15. Expert opinion on NSCLC small specimen biomarker testing — Part 1: Tissue collection and management
16. The International Association for the Study of Lung Cancer Thymic Epithelial Tumor Staging Project: Unresolved Issues to be Addressed for the Next Ninth Edition of the TNM Classification of Malignant Tumors
17. NSCLC Subtyping in Conventional Cytology: Results of the International Association for the Study of Lung Cancer Cytology Working Group Survey to Determine Specific Cytomorphologic Criteria for Adenocarcinoma and Squamous Cell Carcinoma
18. Assistive Communication Device Used During Pediatric Noninvasive Ventilation.
19. The 2021 WHO Classification of Lung Tumors: Impact of Advances Since 2015
20. Comparison of SP142 and 22C3 Immunohistochemistry PD-L1 Assays for Clinical Efficacy of Atezolizumab in Non–Small Cell Lung Cancer: Results From the Randomized OAK Trial
21. Sotorasib versus pembrolizumab in combination with platinum doublet chemotherapy as first-line treatment for metastatic or locally advanced, PD-L1 negative, KRAS G12C-mutated NSCLC (CodeBreaK 202).
22. Molecular testing in stage I–III non-small cell lung cancer: Approaches and challenges
23. Lung cancer mortality reduction by LDCT screening: UKLS randomised trial results and international meta-analysis
24. Prognostic Impact of KRAS G12C Mutation in Patients With NSCLC: Results From the European Thoracic Oncology Platform Lungscape Project
25. Large cell neuroendocrine lung carcinoma: consensus statement from The British Thoracic Oncology Group and the Association of Pulmonary Pathologists
26. The International Association for the Study of Lung Cancer Global Survey on Programmed Death-Ligand 1 Testing for NSCLC
27. The evolving landscape of biomarker testing for non-small cell lung cancer in Europe
28. Evaluation of NGS and RT-PCR Methods for ALK Rearrangement in European NSCLC Patients: Results from the European Thoracic Oncology Platform Lungscape Project
29. PD-L1 as a biomarker of response to immune-checkpoint inhibitors
30. A Grading System for Invasive Pulmonary Adenocarcinoma: A Proposal From the International Association for the Study of Lung Cancer Pathology Committee
31. Non-interventional LUME-BioNIS study of nintedanib plus docetaxel after chemotherapy in adenocarcinoma non-small cell lung cancer: A subgroup analysis in patients with prior immunotherapy
32. The Promises and Challenges of Tumor Mutation Burden as an Immunotherapy Biomarker: A Perspective from the International Association for the Study of Lung Cancer Pathology Committee
33. The International Association for the Study of Lung Cancer Global Survey on Molecular Testing in Lung Cancer
34. Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration for PD-L1 Testing in Non-small Cell Lung Cancer
35. Programmed Death-Ligand 1 Immunohistochemistry Assay Comparison Studies in NSCLC: Characterization of the 73-10 Assay
36. Strategies to Modulate MicroRNA Functions for the Treatment of Cancer or Organ Injury
37. Comprehensive Molecular and Pathologic Evaluation of Transitional Mesothelioma Assisted by Deep Learning Approach: A Multi-Institutional Study of the International Mesothelioma Panel from the MESOPATH Reference Center
38. IASLC Multidisciplinary Recommendations for Pathologic Assessment of Lung Cancer Resection Specimens After Neoadjuvant Therapy
39. Programmed death-ligand 1 expression influenced by tissue sample size. Scoring based on tissue microarrays' and cross-validation with resections, in patients with, stage I–III, non-small cell lung carcinoma of the European Thoracic Oncology Platform Lungscape cohort
40. PD-L1 Testing for Lung Cancer in 2019: Perspective From the IASLC Pathology Committee
41. Interobserver Reliability of Programmed Cell Death Ligand-1 Scoring Using the VENTANA PD-L1 (SP263) Assay in NSCLC
42. The IASLC Lung Cancer Staging Project: Analysis of Resection Margin Status and Proposals for Residual Tumor Descriptors for Non–Small Cell Lung Cancer
43. Cytology for PD-L1 testing: A systematic review
44. Basaloid Carcinoma, Lung
45. Squamous Cell Papilloma, Lung
46. Sclerosing Pneumocytoma, Lung
47. Atypical Adenomatous Hyperplasia, Lung
48. Mucous Gland Adenoma, Lung
49. Multifocal Micronodular Pneumocyte Hyperplasia
50. Mucoepidermoid Carcinoma, Lung
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.